









Markets
/
Stocks
/
nasdaq-azta
/

Azenta Inc

AZTA

31.260USD

+0.800+2.63%

Market hours （ET）Quotes delayed by 15 min

1.43BMarket Cap

LossP/E TTM



Azenta Inc

31.260

+0.800+2.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

55 / 507

Overall Ranking

159 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Hold

Current Rating

31.429

Target Price

+2.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and synthesis editing and related services. The B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. The Company provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.15% year-on-year.

Undervalued

The company’s latest PE is -161.56, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 54.83M shares, decreasing 7.81% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.55M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.78, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 143.94M, representing a year-over-year decrease of 16.70%, while its net profit experienced a year-over-year decrease of 702.28%.

Score

Industry at a Glance

Previous score

9.07

Change

-0.29



Financials

9.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -161.56, which is -89.98% below the recent high of -16.18 and 45.81% above the recent low of -87.55.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.25, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Azenta Inc is 30.00, with a high of 40.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

6.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Hold

Current Rating

31.429

Target Price

+3.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Azenta Inc

AZTA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.93, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 31.98 and the support level at 28.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.76

Change

0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.220

Neutral

RSI(14)

50.976

Neutral

STOCH(KDJ)(9,3,3)

59.743

Neutral

ATR(14)

1.154

High Vlolatility

CCI(14)

112.816

Buy

Williams %R

35.395

Buy

TRIX(12,20)

-0.105

Sell

StochRSI(14)

51.160

Neutral

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

30.372

Buy

MA10

29.987

Buy

MA20

30.128

Buy

MA50

31.070

Buy

MA100

29.853

Buy

MA200

36.605

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 119.61%, representing a quarter-over-quarter increase of 0.23%. The largest institutional shareholder is The Vanguard, holding a total of 4.55M shares, representing 9.93% of shares outstanding, with 0.75% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.96M

-5.86%

Politan Capital Management, L.P.

4.62M

+0.09%

The Vanguard Group, Inc.

Star Investors

4.42M

-1.98%

Dimensional Fund Advisors, L.P.

2.92M

-3.64%

Conestoga Capital Advisors, LLC

1.92M

+21.40%

State Street Global Advisors (US)

1.56M

-11.14%

Allspring Global Investments, LLC

994.32K

-24.52%

GW&K Investment Management, LLC

1.29M

-0.73%

Lord, Abbett & Co. LLC

1.01M

+6.32%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.21, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.64. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.